Perrigo Co. (PRGO) said Tuesday it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to Vanos® Cream 0.1%.
Perrigo said it was awarded 180-days of generic drug exclusivity. Perrigo had previously resolved litigation with the brand and has commenced shipment of the product.
Vanos® Cream 0.1% (fluocinonide cream 0.1%) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older and has estimated annual sales of about $107 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.